Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
BMC Health Serv Res ; 23(1): 679, 2023 Jun 22.
Article in English | MEDLINE | ID: mdl-37349809

ABSTRACT

BACKGROUND: Postpartum depression is a risk factor for suicide and maltreatment of children, and its early detection and appropriate intervention are issues to be resolved. In Japan, local governments are working to detect postpartum depression early by conducting home visits to families with infants within 4 months postpartum, but home-visit professionals have faced new difficulties due to the coronavirus disease 2019 (COVID-19) pandemic that started in 2020. The purpose of this study was to clarify the difficulties experienced by health care professionals who perform home visits to screen for postpartum depression. METHODS: Focus-group interviews were conducted during the COVID-19 pandemic with health care professionals (n = 13) who make postpartum home visits to families with infants within 4 months. Data were analyzed using thematic analysis. RESULTS: Four main categories were identified that describe the difficulties experienced by health care professionals: "Lack of support for partners," "Difficulty in talking face-to-face," "Inability to offer family assistance," and "Anxiety about being a source of infection." CONCLUSIONS: This study shed light on the difficulties faced by professionals in supporting mothers and children in the community during the COVID-19 pandemic. Although these difficulties were considered to have become apparent during the pandemic, the results may offer an important perspective for postpartum mental health support even after the pandemic ends. Accordingly, it may be necessary for these professionals to receive supported through multidisciplinary collaboration in order to improve postpartum care in the community.


Subject(s)
COVID-19 , Depression, Postpartum , Infant , Female , Child , Humans , Depression, Postpartum/diagnosis , Depression, Postpartum/epidemiology , COVID-19/epidemiology , Pandemics , House Calls , Japan/epidemiology , Postpartum Period , Health Personnel/psychology
3.
J Obstet Gynaecol Res ; 47(10): 3524-3531, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34237800

ABSTRACT

AIM: This study aims to examine the prevalence of postpartum depression and its relationship with social support adjusted for self-perceived impact of COVID-19 in parturient women admitted to a perinatal medical center in Japan. METHODS: This cross-sectional study included 513 women who underwent a 1-month postpartum checkup between August 3 and November 27, 2020. Postpartum depression was measured using the Edinburgh Postnatal Depression Scale. Social support was measured using the Multidimensional Scale of Perceived Social Support and the score was dichotomized using the Youden index. Nineteen demographic and obstetric characteristics were also assessed. RESULTS: Postpartum depression was observed in 35 (7.6%) of 461 women: 25 (26.6%) and 10 (2.7%) in the low- and high-support groups, respectively. Women in the low-support group were significantly more likely to have postpartum depression than those in the high-support group (odds ratio [OR], 11.7; 95% confidence interval [CI], 5.4-27.3; p < 0.001). Furthermore, no interaction was observed between social support and the impact of COVID-19 for postpartum depression (p = 0.32). CONCLUSIONS: The prevalence of postpartum depression in the study institution was lower than that reported by previous studies in Japan. Moreover, social support was an important predictive factor for postpartum depression during the COVID-19 pandemic.


Subject(s)
COVID-19 , Depression, Postpartum , Cross-Sectional Studies , Depression , Depression, Postpartum/epidemiology , Female , Humans , Pandemics , Postpartum Period , Pregnancy , Risk Factors , SARS-CoV-2 , Social Support
4.
BMC Health Serv Res ; 17(1): 40, 2017 01 17.
Article in English | MEDLINE | ID: mdl-28095906

ABSTRACT

BACKGROUND: Physician-led home visit care with medical teams (Zaitaku care) has been developed on a national scale to support those who wish to stay at home at the end of life, and promote a system of community-based integrated care in Japan. Medical care at the end of life can be expensive, and is an urgent socioeconomic issue for aging societies. However medical costs of physician-led home visits care have not been well studied. We compared the medical costs of Zaitaku care and hospital care at the end of life in a rapidly aging community in a rural area in Japan. METHODS: A cross-sectional study was performed to compare the total medical costs during patients' final days of life (30 days or less) between Zaitaku care and hospital care from September 2012 to August 2013 in Fukuoka Prefecture, Japan. RESULTS: Thirty four patients died at home under Zaitaku care, and 72 patients died in the hospital during this period. The average daily cost of care during the last 30 days did not differ significantly between the two groups. Although Zaitaku care costs were higher than hospital care costs in the short-term (≦10 days, Zaitaku care $371.2 vs. Hospital care $202.0, p = 0.492), medical costs for Zaitaku care in the long-term care (≧30 days) were less than that of hospital care ($155.8 vs. $187.4, p = 0.055). CONCLUSIONS: Medical costs of Zaitaku care were less compared with hospital care if incorporated early for long term care, but it was high if incorporated late for short term care. For long term care, medical costs for Zaitaku care was 16.7% less than for hospitalization at the end of life. This physician-led home visit care model should be an available option for patients who wish to die at home, and may be beneficial financially over time.


Subject(s)
Home Care Services/economics , Hospital Costs , House Calls/economics , Terminal Care , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Hospitalization/economics , Humans , Japan , Long-Term Care , Male , Physicians , Postnatal Care , Residence Characteristics
5.
Blood ; 111(3): 1182-92, 2008 Feb 01.
Article in English | MEDLINE | ID: mdl-17975014

ABSTRACT

The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels in leukemia stem cells from patients with myeloid leukemia. CREB transgenic mice develop myeloproliferative disease after 1 year, but not leukemia, suggesting that CREB contributes to but is not sufficient for leukemogenesis. Here, we show that CREB is most highly expressed in lineage negative hematopoietic stem cells (HSCs). To understand the role of CREB in hematopoietic progenitors and leukemia cells, we examined the effects of RNA interference (RNAi) to knock down CREB expression in vitro and in vivo. Transduction of primary HSCs or myeloid leukemia cells with lentiviral CREB shRNAs resulted in decreased proliferation of stem cells, cell- cycle abnormalities, and inhibition of CREB transcription. Mice that received transplants of bone marrow transduced with CREB shRNA had decreased committed progenitors compared with control mice. Mice injected with Ba/F3 cells expressing either Bcr-Abl wild-type or T315I mutation with CREB shRNA had delayed leukemic infiltration by bioluminescence imaging and prolonged median survival. Our results suggest that CREB is critical for normal myelopoiesis and leukemia cell proliferation.


Subject(s)
Cyclic AMP Response Element-Binding Protein/metabolism , Hematopoiesis , Leukemia/metabolism , Leukemia/pathology , Animals , Cell Line , Cell Proliferation , Cyclic AMP Response Element-Binding Protein/genetics , Cyclin A/metabolism , Cyclin D1/metabolism , Gene Expression Regulation , Humans , Leukemia/genetics , Mice , Mice, Inbred C57BL , RNA Interference , Survival Rate
6.
Stem Cells ; 25(5): 1213-21, 2007 May.
Article in English | MEDLINE | ID: mdl-17218403

ABSTRACT

Mesenchymal stem cells (MSC), a distinct type of adult stem cell, are easy to isolate, culture, and manipulate in ex vivo culture. These cells have great plasticity and potential for therapeutic application, but their properties are poorly understood because of their low frequency and the lack of knowledge on cell surface markers and their location of origin. The present study was designed to address the undefined lineage relationship of hematopoietic and mesenchymal stem cells. Genetically marked, highly purified hematopoietic stem cells (HSCs) were transplanted into wild-type animals and, after bone marrow repopulation, the progeny were rigorously investigated for differentiation potential into mesenchymal tissues by analyzing in vitro differentiation into mesenchymal tissues. None/very little of the hematopoietic cells contributed to colony-forming units fibroblast activity and mesenchymal cell differentiation; however, unfractionated bone marrow cells resulted in extensive replacement of not only hematopoietic cells but also mesenchymal cells, including MSCs. As a result, we concluded that purified HSCs have no significant potency to differentiate into mesenchymal lineage. The data strongly suggest that hematopoietic cells and mesenchymal lineage cells are derived from individual lineage-specific stem cells. In addition, we succeeded in visualizing mesenchymal lineage cells using in vivo microimaging and immunohistochemistry. Flow cytometric analysis revealed CD140b (PDGFRbeta) could be a specific marker for mesenchymal lineage cells. The results may reinforce the urgent need for a more comprehensive view of the mesenchymal stem cell identity and characteristics. Disclosure of potential conflicts of interest is found at the end of this article.


Subject(s)
Bone Marrow Cells/cytology , Cell Lineage , Stem Cells/cytology , Animals , Biomarkers/metabolism , Cell Adhesion , Colony-Forming Units Assay , Flow Cytometry , Gene Expression Regulation , Green Fluorescent Proteins/metabolism , Hematopoietic System/cytology , Mice , Mice, Inbred C57BL , Phenotype , Transcription Factors/genetics , Transcription Factors/metabolism
7.
Cell Cycle ; 4(9): 1134-5, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16096372

ABSTRACT

Cyclic-AMP response element binding protein (CREB) is a transcription factor that functions in glucose homeostasis, growth-factor- dependent cell survival, proliferation and memory. Signaling by hematopoietic growth factors, such as GM-CSF, results in activation of CREB and upregulation of CREB target genes. Data from our laboratory shows that a majority of patients with acute lymphoid and myeloid leukemia overexpress CREB in the bone marrow. CREB overexpression is associated with poor initial outcome of clinical disease in AML patients. To study its role in hematopoiesis, we overexpressed CREB in leukemia cell lines and in mice. CREB overexpression resulted in increased survival and proliferation of myeloid cells and blast-transformation of bone marrow progenitor cells from transgenic mice expressing CREB in the myeloid lineage. CREB transgenic mice also develop myeloproliferative disease after one year. Thus, CREB acts as a proto-oncogene to regulate hematopoiesis and contributes to the leukemia phenotype. Our results suggest that CREB-dependent pathways may serve as targets for directed therapies in leukemia in the future.


Subject(s)
Cyclic AMP Response Element-Binding Protein/physiology , Hematopoiesis , Animals , Bone Marrow Cells/metabolism , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cell Transformation, Neoplastic , Cyclic AMP Response Element-Binding Protein/metabolism , Gene Expression Regulation, Neoplastic , Glucose/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Leukemia, Myeloid, Acute/metabolism , Mice , Mice, Transgenic , Neoplasms/metabolism , Phenotype , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Proto-Oncogene Mas , Proto-Oncogene Proteins/chemistry , Signal Transduction , Up-Regulation
8.
Cancer Cell ; 7(4): 351-62, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15837624

ABSTRACT

CREB is a transcription factor that functions in glucose homeostasis, growth factor-dependent cell survival, and memory. In this study, we describe a role of CREB in human cancer. CREB overexpression is associated with increased risk of relapse and decreased event-free survival. CREB levels are elevated in blast cells from patients with acute myeloid leukemia. To understand the role of CREB in leukemogenesis, we studied the biological consequences of CREB overexpression in primary human leukemia cells, leukemia cell lines, and transgenic mice. Our results demonstrate that CREB promotes abnormal proliferation and survival of myeloid cells in vitro and in vivo through upregulation of specific target genes. Thus, we report that CREB is implicated in myeloid cell transformation.


Subject(s)
Hematopoiesis/physiology , Leukemia, Myeloid/physiopathology , Proto-Oncogenes/physiology , Transcription Factors/physiology , ATP-Binding Cassette Transporters/genetics , Acute Disease , Animals , Bone Marrow Cells/metabolism , Cell Differentiation/genetics , Cell Differentiation/physiology , Cell Line, Tumor , Cell Proliferation , Cell Survival/genetics , Cell Survival/physiology , Cyclic AMP Response Element-Binding Protein , Cyclin A/metabolism , Down-Regulation/genetics , Gene Expression/genetics , Humans , Leukemia, Myeloid/genetics , Leukemia, Myeloid/metabolism , Leukocyte Count , Mice , Mice, Transgenic , Models, Biological , Myeloid Cells/metabolism , Myeloid Cells/pathology , Myeloproliferative Disorders/genetics , Myeloproliferative Disorders/metabolism , Myeloproliferative Disorders/pathology , Phosphorylation , Proto-Oncogene Mas , Proto-Oncogenes/genetics , RNA, Small Interfering/genetics , Spleen/pathology , Transcription Factors/genetics , Transcription Factors/metabolism , Transfection , Tumor Cells, Cultured , Up-Regulation/genetics
9.
Haematologica ; 90(3): 317-25, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15749663

ABSTRACT

BACKGROUND AND OBJECTIVES: The aim of this study was to investigate the possibility of green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG) as a novel therapeutic agent for the patients with myeloid leukemia. DESIGN AND METHODS: We investigated the effects of EGCG on the induction of apoptosis in leukemic cells in vitro and in vivo. We further examined the molecular mechanisms of EGCG-induced apoptosis in myeloid leukemic cells. RESULTS: EGCG rapidly induced apoptotic cell death in retinoic acid (RA)-resistant acute promyelocytic leukemia (APL), UF-1 cells within 3 h. EGCG induced apoptosis in UF-1 cells was in association with the loss of mitochondrial transmembrane potentials (Deltapsim) and activation of caspase-3 and -9. Elevation of intracellular reactive oxygen species (ROS) production was also demonstrated during EGCG-induced apoptosis of UF-1 as well as fresh myeloid leukemic cells. In NOD/SCID mice transplanted with UF-1 cells, EGCG effectively inhibited tumor growth in vivo, and the number of mitoses among the cells significantly decreased in comparison to that of control mouse cells. INTERPRETATION AND CONCLUSIONS: In summary, EGCG has potential as a novel therapeutic agent for myeloid leukemia via induction of apoptosis mediated by modification of the redox system.


Subject(s)
Apoptosis/drug effects , Catechin/pharmacology , Leukemia, Myeloid/drug therapy , Animals , Catechin/administration & dosage , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Leukemia, Myeloid/pathology , Mice , Mice, SCID , Reactive Oxygen Species/metabolism , Transplantation, Heterologous
10.
Blood ; 104(12): 3581-7, 2004 Dec 01.
Article in English | MEDLINE | ID: mdl-15297308

ABSTRACT

Bone marrow (BM) cells are reported to contribute to the process of regeneration following myocardial infarction. However, the responsible BM cells have not been fully identified. Here, we used 2 independent clonal studies to determine the origin of bone marrow (BM)-derived cardiomyocytes. First, we transplanted single CD34(-) c-kit(+)Sca-1(+) lineage(-) side population (CD34(-)KSL-SP) cells or whole BM cells from mice ubiquitously expressing enhanced green fluorescent protein (EGFP) into lethally irradiated mice, induced myocardial infarction (MI), and treated the animals with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the damaged myocardium. At 8 weeks after MI, from 100 specimens we counted only 3 EGFP(+) actinin(+) cells in myocardium of CD34(-) KSL-SP cells in mice that received transplants, but more than 5000 EGFP(+) actinin(+) cells in whole BM cell in mice that received transplants, suggesting that most of EGFP(+) actinin(+) cells were derived from nonhematopoietic BM cells. Next, clonally purified nonhematopoietic mesenchymal stem cells (MSCs), cardiomyogenic (CMG) cells, that expressed EGFP in the cardiomyocyte-specific manner were transplanted directly into BM of lethally irradiated mice, MI was induced, and they were treated with G-CSF. EGFP(+) actinin(+) cells were observed in the ischemic myocardium, indicating that CMG cells had been mobilized and differentiated into cardiomyocytes. Together, these results suggest that the origin of the vast majority of BM-derived cardiomyocytes is MSCs.


Subject(s)
Chemotaxis , Mesenchymal Stem Cells/cytology , Myocardial Infarction/pathology , Myocytes, Cardiac/pathology , Myocytes, Cardiac/physiology , Animals , Bone Marrow Transplantation , Cell Differentiation , Cell Lineage , Granulocyte Colony-Stimulating Factor/administration & dosage , Green Fluorescent Proteins/genetics , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/physiology , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Myocytes, Cardiac/metabolism , Regeneration
11.
Immunity ; 20(1): 87-93, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14738767

ABSTRACT

Single-cell transplantation analysis revealed that the cells that had the strongest dye efflux activity ("Tip"-SP cells) and had the phenotype CD34- c-Kit+ Sca-1+ Lin- (CD34- KSL cells) exhibited very strong proliferation and multilineage differentiation capacity. Ninety-six percent of the lethally irradiated mice that received a single "Tip"-SP CD34- KSL cell showed significant donor cell engraftment for long term. These findings support the hypothesis that "Tip"-SP CD34- KSL cells represent the most primitive hematopoietic stem cells that are capable of migrating into the primary site and surviving and/or proliferating with nearly absolute efficiency. This led us to propose high marrow-seeding efficiency as a specific characteristic of primitive HSCs, in addition to their self-renewal and multipotent capacity.


Subject(s)
Cell Movement , Graft Survival , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Animals , Antigens, CD34 , Cell Differentiation/physiology , Cell Division/physiology , Cell Separation/methods , Fluorescent Dyes , Hematopoietic Stem Cells/physiology , Mice , Mice, Inbred C57BL , Phenotype , Staining and Labeling
12.
Exp Hematol ; 32(1): 45-51, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14725900

ABSTRACT

OBJECTIVE: All-trans retinoic acid (ATRA) has been used as the first-line therapy for patients with acute promyelocytic leukemia (APL). We previously reported that ATRA increased serum thrombopoietin (TPO) levels accompanied by thrombocytosis during ATRA therapy for APL. In this study, we investigated the mechanism of transcriptional regulation of TPO gene by ATRA using human bone marrow stromal cells. PATIENTS AND METHODS: Real time reverse transcriptase polymerase chain reaction and Western blotting were performed to quantify TPO mRNA and protein levels in cells from the human bone marrow stromal cell line KM101. Luciferase-based reporter assay, electrophoretic mobility shift assay (EMSA), and chromatin immunoprecipitation (ChIP) assay were performed to identify a retinoic acid responsive element in the promoter region of TPO gene (TPO-RARE). RESULTS: TPO mRNA expression was up-regulated by approximately 2.9 times 8 hours after stimulation with 10(-6) M ATRA in KM101 cells. In contrast, ATRA did not alter TPO mRNA expression in cells from the human hepatoma cell line HepG2. Protein level of KM101 cells also was increased with 10(-6) M ATRA for 48 hours in KM101 cells. We found the synthesized RARalpha protein bound to [gamma-32P]-labeled TPO-RARE probe and its binding was competed by adding 200x amount of cold TPO-RARE probe by EMSA. In addition, [gamma-32P]-labeled TPO-RARE probe bound to KM101 nuclear protein extract was supershifted by anti-RARalpha antibody and modified by treatment with ATRA. The relative luciferase activity of TPO gene was increased by 2.2x and the histone H4 was acetylated through TPO-RARE after ATRA stimulation in KM101 cells by ChIP assay. CONCLUSION: These data support the direct up-regulation of TPO transcription by ATRA stimulation in human bone marrow stromal cells and propose one of the mechanisms of thrombocytosis during ATRA therapy for APL.


Subject(s)
Bone Marrow Cells/drug effects , Gene Expression Regulation/drug effects , Thrombopoietin/genetics , Tretinoin/pharmacology , 5' Flanking Region , Bone Marrow Cells/metabolism , Cells, Cultured , Humans , Receptors, Retinoic Acid , Retinoic Acid Receptor alpha , Stromal Cells/drug effects , Transcription, Genetic/drug effects , Up-Regulation
13.
J Cell Physiol ; 191(3): 327-35, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12012328

ABSTRACT

Recent studies have shown that point mutations in granulocyte colony-stimulating factor receptor (G-CSFR) are involved in the pathogenesis of severe congenital neutropenia (SCN) and in the transformation of SCN to acute myelogenous leukemia (AML). It is reasonably speculated that the abnormalities in the signal transduction pathways for G-CSF could be partly responsible for the pathogenesis and the development to AML in patients with myelodysplastic syndromes (MDS). Therefore, we investigated the structural and functional abnormalities of the G-CSFR in 14 patients with MDS and 10 normal subjects. In in vitro colony forming assay, MDS samples showed reduced response to growth factors. However, G-CSF, but not GM-CSF and IL-3, enhanced clonal growth in three cases of high risk patients with MDS (RAEB, RAEB-t, and MDS having progressed to acute myeloid leukemia (AML)) and one low risk patient (RA). Eight out of 14 patients including above 4 patients demonstrated a common deletion of the G-CSFR cDNA; a deletion of three nucleotides (2128-2130) in the juxtamembrane domain of the G-CSFR, which resulted in a conversion of Asn(630)Arg(631) to Lys(630). To assess the functional activities of this deletion in the G-CSFR isoform, a mutant with the same three-nucleotide deletion was constructed by site-directed mutagenesis. FDCP-2 cells expressing the G-CSFR isoform responded to G-CSF, and exhibited proliferative responses than did those cells having wild-type G-CSFR. Moreover, these isoforms showed prolonged activation of STAT3 in response to G-CSF than did the wild-type. These results suggest that the deletion in the juxtamembrane domain of the G-CSFR gives a growth advantage to abnormal MDS clones and may contribute to the pathogenesis of MDS.


Subject(s)
Mutation/physiology , Myelodysplastic Syndromes/metabolism , Receptors, Granulocyte Colony-Stimulating Factor/genetics , Amino Acid Sequence/genetics , Base Sequence/genetics , Cell Division/physiology , Clone Cells , DNA/genetics , DNA-Binding Proteins/physiology , Humans , Kinetics , Molecular Sequence Data , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , STAT3 Transcription Factor , Trans-Activators/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...